FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555763363> ?p ?o ?g. }

• W2555763363 endingPage "85305" @default.
• W2555763363 startingPage "85291" @default.
• W2555763363 abstract "// Eric T. Alexander 1 , Allyson R. Minton 1 , Molly C. Peters 1 , Joanne van Ryn 2 , Susan K. Gilmour 1 1 Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA 2 Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany Correspondence to: Susan K. Gilmour, email: gilmours@mlhs.org Keywords: thrombin, immunosuppression, MDSCs, ovarian cancer, dabigatran Received: May 27, 2016      Accepted: October 26, 2016      Published: November 11, 2016 ABSTRACT Cancer is often associated with an increased risk of thrombotic complications which can be aggravated by treatment with chemotherapeutics such as cisplatin. Multiple lines of evidence suggest that thrombin activity promotes tumor growth and metastasis. We examined the effect of co-treatment with dabigatran etexilate, a direct thrombin inhibitor, and cisplatin using the murine ID8 ovarian cancer model. Mice receiving co-treatment with both dabigatran etexilate and low dose cisplatin had significantly smaller tumors, developed less ascites and had lower levels of circulating activated platelets and tissue factor (TF) positive microparticles than those treated with dabigatran etexilate or cisplatin alone. Co-treatment with dabigatran etexilate and cisplatin significantly decreased the number of Gr1 + /CD11b + myeloid derived suppresser cells and CD11b + /CD11c + dendritic cells in the ascites of ID8 tumor-bearing mice. Co-treatment also significantly reduced levels of pro-tumorigenic cytokines including TGF-β, VEGF, IL-6, IL-10, and MCP-1 in the ascites while increasing IFN-γ production by CD8 + effector T cells in the tumor ascites. These results demonstrate that co-treatment with dabigatran etexilate significantly augments the anti-tumor activity of cisplatin in ovarian tumor progression by alleviating the immunosuppressive microenvironment, suggesting that thrombin may be a potential therapeutic target for treatment of ovarian cancer." @default.
• W2555763363 created "2016-11-30" @default.
• W2555763363 creator A5015982890 @default.
• W2555763363 creator A5022667997 @default.
• W2555763363 creator A5037293929 @default.
• W2555763363 creator A5050661239 @default.
• W2555763363 creator A5062928914 @default.
• W2555763363 date "2016-11-11" @default.
• W2555763363 modified "2023-10-10" @default.
• W2555763363 title "Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment" @default.
• W2555763363 cites W1494453913 @default.
• W2555763363 cites W1543468608 @default.
• W2555763363 cites W1562986705 @default.
• W2555763363 cites W1577533565 @default.
• W2555763363 cites W1641613989 @default.
• W2555763363 cites W1963938486 @default.
• W2555763363 cites W1966556597 @default.
• W2555763363 cites W1975265095 @default.
• W2555763363 cites W1975441923 @default.
• W2555763363 cites W1976036895 @default.
• W2555763363 cites W1977618015 @default.
• W2555763363 cites W1981090858 @default.
• W2555763363 cites W1986268903 @default.
• W2555763363 cites W1989528047 @default.
• W2555763363 cites W1997815012 @default.
• W2555763363 cites W2005112283 @default.
• W2555763363 cites W2005967493 @default.
• W2555763363 cites W2009211019 @default.
• W2555763363 cites W2009489671 @default.
• W2555763363 cites W2032651612 @default.
• W2555763363 cites W2033377234 @default.
• W2555763363 cites W2034995931 @default.
• W2555763363 cites W2036655503 @default.
• W2555763363 cites W2042633087 @default.
• W2555763363 cites W2045819100 @default.
• W2555763363 cites W2051582909 @default.
• W2555763363 cites W2054146518 @default.
• W2555763363 cites W2058468432 @default.
• W2555763363 cites W2058689113 @default.
• W2555763363 cites W2059215414 @default.
• W2555763363 cites W2061638485 @default.
• W2555763363 cites W2064684260 @default.
• W2555763363 cites W2064693934 @default.
• W2555763363 cites W2068773189 @default.
• W2555763363 cites W2074707530 @default.
• W2555763363 cites W2075131034 @default.
• W2555763363 cites W2076243964 @default.
• W2555763363 cites W2077255241 @default.
• W2555763363 cites W2078558642 @default.
• W2555763363 cites W2081491399 @default.
• W2555763363 cites W2083814433 @default.
• W2555763363 cites W2093504658 @default.
• W2555763363 cites W2095818256 @default.
• W2555763363 cites W2101185555 @default.
• W2555763363 cites W2109339951 @default.
• W2555763363 cites W2116668909 @default.
• W2555763363 cites W2121080406 @default.
• W2555763363 cites W2124422993 @default.
• W2555763363 cites W2124551895 @default.
• W2555763363 cites W2141768998 @default.
• W2555763363 cites W2142874979 @default.
• W2555763363 cites W2149562718 @default.
• W2555763363 cites W2152400371 @default.
• W2555763363 cites W2152663709 @default.
• W2555763363 cites W2165506983 @default.
• W2555763363 cites W2170720046 @default.
• W2555763363 cites W2172191543 @default.
• W2555763363 cites W2263520041 @default.
• W2555763363 cites W2332292914 @default.
• W2555763363 cites W2411537421 @default.
• W2555763363 doi "https://doi.org/10.18632/oncotarget.13300" @default.
• W2555763363 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5356737" @default.
• W2555763363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27852034" @default.
• W2555763363 hasPublicationYear "2016" @default.
• W2555763363 type Work @default.
• W2555763363 sameAs 2555763363 @default.
• W2555763363 citedByCount "38" @default.
• W2555763363 countsByYear W25557633632017 @default.
• W2555763363 countsByYear W25557633632018 @default.
• W2555763363 countsByYear W25557633632019 @default.
• W2555763363 countsByYear W25557633632020 @default.
• W2555763363 countsByYear W25557633632021 @default.
• W2555763363 countsByYear W25557633632022 @default.
• W2555763363 countsByYear W25557633632023 @default.
• W2555763363 crossrefType "journal-article" @default.
• W2555763363 hasAuthorship W2555763363A5015982890 @default.
• W2555763363 hasAuthorship W2555763363A5022667997 @default.
• W2555763363 hasAuthorship W2555763363A5037293929 @default.
• W2555763363 hasAuthorship W2555763363A5050661239 @default.
• W2555763363 hasAuthorship W2555763363A5062928914 @default.
• W2555763363 hasBestOaLocation W25557633631 @default.
• W2555763363 hasConcept C121608353 @default.
• W2555763363 hasConcept C126322002 @default.
• W2555763363 hasConcept C203014093 @default.
• W2555763363 hasConcept C2776107976 @default.
• W2555763363 hasConcept C2776301958 @default.
• W2555763363 hasConcept C2776694085 @default.
• W2555763363 hasConcept C2778239845 @default.

• next